Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
B
BOLD
vs
S&P 500
S&P 500
Over the past 12 months, BOLD has significantly outperformed S&P 500, delivering a return of +104% compared to S&P 500's +19% growth.
Stocks Performance
BOLD vs S&P 500
Performance Gap
BOLD vs S&P 500
Performance By Year
BOLD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Boundless Bio Inc
Glance View
Boundless Bio is a cancer drug developer focused on a specific genetic problem called extrachromosomal DNA, or ecDNA. In some tumors, cancer genes sit on small DNA circles outside the normal chromosomes, and that can help the cancer grow and resist treatment. The company is trying to build medicines that stop cancers that depend on this DNA structure, especially solid tumors with hard-to-treat genetic changes. The company does not sell a finished drug product like a traditional drugmaker. Its business is to discover and develop drug candidates through its own research platform, then move the most promising ones into clinical testing. If its programs succeed, Boundless Bio can make money through future drug sales, licensing deals, or partnerships with larger pharmaceutical companies. Its main customers are not end patients today but the healthcare system and, eventually, cancer specialists and drug makers if its therapies are approved or partnered. What makes Boundless Bio different is its narrow focus on ecDNA biology, which gives it a very specific place in the oncology value chain: it is trying to turn a newly understood cancer mechanism into targeted medicines.